This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HYPR Achieves Positive Swoop System Data for ECMO: Stock to Rise?
by Zacks Equity Research
Hyperfine announces a publication on using the Swoop system for patients on ECMO support. The study showed the safety of using an ultra-low-field portable brain MRI on patients undergoing ECMO.
Here's Why You Should Add BSX Stock to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
by Zacks Equity Research
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
Global Expansion, Strategic Innovations Aid Boston Scientific Stock
by Zacks Equity Research
We are impressed with BSX's recent acquisitions that have added numerous products with immense potential.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
by Zacks Equity Research
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
by Zacks Equity Research
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
by Zacks Equity Research
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
by Zacks Equity Research
BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.
RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions
by Zacks Equity Research
ResMed introduces digital and personalized solutions designed to improve sleep health.
Positive Trial Outcome for PulseSelect PFA Likely to Boost MDT Stock
by Zacks Equity Research
Medtronic presents new clinical data on the PulseSelect PFA System and marks its launch in Japan.
BSX Stock Gains From FARAPULSE PFA's PMDA Approval in Japan
by Zacks Equity Research
Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.
HOLX Stock Gains From New Offerings Despite Macro Issues
by Zacks Equity Research
In Breast Health, Hologic expands its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery.
Is HOLX Stock a Smart Hold for Your Portfolio Right Now?
by Zacks Equity Research
Hologic's strength in Molecular Diagnostics is highly promising. Yet, macroeconomic uncertainties can pose headwinds for its operations.
VRNOF Stock Likely to Gain From Its Newly Opened Dispensary in Phoenix
by Zacks Equity Research
Verano is set to open a new Zen Leaf Arcadia in Phoenix, AZ, today. Zen Leaf Arcadia is located at 2710 E Indian School Road, Phoenix. It will be open daily from 8 a.m. to 10 p.m. local time.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels
by Zacks Equity Research
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
Favorable Data on Swoop Portable MRI Likely to Support Hyperfine Stock
by Zacks Equity Research
Compared to conventional MRI, which takes an average of 27.7 hours, the Swoop system of HYPR operates with a median time-to-scan of 2.5 hours.
MDT Stock Might Gain From Expanded AiBLE Ecosystem and New Partnership
by Zacks Equity Research
Medtronic expands AiBLE spine surgery ecosystem with new technologies and a partnership with Siemens Healthineers.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
by Zacks Equity Research
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
Here's Why You Should Add HAE Stock in Your Portfolio Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
Inspira Stock to Gain From its Appearance at Annual ELSO Conference
by Zacks Equity Research
At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.
Exclusive Partnership With Pair Eyewear Likely to Support EYE Stock
by Zacks Equity Research
National Vision's America's Best stores become the exclusive retail partner of Pair Eyewear.
Quest Diagnostics Stock Gains From New Offerings, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.
Should You Continue to Retain LH Stock in Your Portfolio?
by Zacks Equity Research
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
by Zacks Equity Research
Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.